NewAmsterdam Pharma Company N.V. Ordinary Shares Asset Resilience Ratio
NewAmsterdam Pharma Company N.V. Ordinary Shares asset resilience ratio. NewAmsterdam Pharma Company N.V. Ordinary Shares (NAMS) has an Asset Resilience Ratio of 20.92% as of September 2025. The Asset Resilience Ratio measures the percentage of a company's total assets that are held in liquid form (cash and short-term investments). This metric indicates how well-positioned the company is to handle unexpected financial challenges, economic downturns, or strategic opportunities without requiring external financing. Read NAMS current and long-term liabilities for a breakdown of total debt and financial obligations.
Liquid Assets
Total Assets
Resilience Assessment
Asset Resilience Ratio of NewAmsterdam Pharma Company N.V. Ordinary Shares (2023–2024)
Asset resilience ratio of NewAmsterdam Pharma Company N.V. Ordinary Shares from 2023 to 2024. This chart shows how NewAmsterdam Pharma Company N.V. Ordinary Shares's Asset Resilience Ratio has changed over time. See how much free cash does NewAmsterdam Pharma Company N.V. Ordinar generate to measure how efficiently the company converts operating cash flow to free cash.
Liquid Assets Composition Over Time
This chart breaks down NewAmsterdam Pharma Company N.V. Ordinary Shares's liquid assets into cash & equivalents and short-term investments, showing how the composition has evolved over time. For the complete balance sheet picture, see NewAmsterdam Pharma Company N.V. Ordinar assets under control.
Current Liquid Assets Breakdown
| Component | Amount | % of Total Assets |
|---|---|---|
| Cash & Equivalents | $0.00 | 0% |
| Short-term Investments | $164.54 Million | 20.92% |
| Total Liquid Assets | $164.54 Million | 20.92% |
Asset Resilience Insights
- Good Liquidity Position: NewAmsterdam Pharma Company N.V. Ordinary Shares maintains a healthy 20.92% of assets in liquid form.
- This level provides good financial flexibility while maintaining productive asset deployment.
- The company has significant short-term investments, indicating active treasury management.
NewAmsterdam Pharma Company N.V. Ordinary Shares Industry Peers by Asset Resilience Ratio
Compare NewAmsterdam Pharma Company N.V. Ordinary Shares's asset resilience ratio with other companies in the same industry.
| Company | Industry | Asset Resilience Ratio |
|---|---|---|
|
Biomarin Pharmaceutical Inc
NASDAQ:BMRN |
Biotechnology | 0.00% |
|
Tubize-Fin
BR:TUB |
Biotechnology | 2.50% |
|
BB Biotech AG
SW:BION |
Biotechnology | 92.97% |
|
Xiamen Amoytop Biotech Co Ltd
SHG:688278 |
Biotechnology | 4.69% |
|
Innovita Biological Technology Co. Ltd. A
SHG:688253 |
Biotechnology | 65.12% |
|
Jiangsu Aidea Pharmaceutical Co Ltd
SHG:688488 |
Biotechnology | 4.57% |
|
Eupraxia Pharmaceuticals Inc
TO:EPRX |
Biotechnology | 25.13% |
|
Cabio Biotech Wuhan Co Ltd
SHG:688089 |
Biotechnology | 3.60% |
NewAmsterdam Pharma Company N.V. Ordinary Shares Asset Resilience Ratio by Year (2023–2024)
NewAmsterdam Pharma Company N.V. Ordinary Shares asset resilience ratio by year from 2023 to 2024. The table below shows the annual Asset Resilience Ratio data for NewAmsterdam Pharma Company N.V. Ordinary Shares.
| Year | Asset Resilience Ratio (%) | Liquid Assets | Total Assets | Change |
|---|---|---|---|---|
| 2024-12-31 | 7.22% | $62.45 Million | $864.62 Million | -- |
| 2023-12-31 | 0.00% | $0.00 | $347.10 Million | -- |
About NewAmsterdam Pharma Company N.V. Ordinary Shares
NewAmsterdam Pharma Company N.V., a late-stage biopharmaceutical company, develops therapies to enhance patient care in populations with metabolic disease. It is developing obicetrapib, an oral low-dose cholesteryl ester transfer protein (CETP) inhibitor, that is in various clinical trials as a monotherapy and a combination therapy with ezetimibe for lowering LDL-C for cardiovascular diseases. Th… Read more